Publicaciones en las que colabora con Miguel Ángel Sanz Alonso (20)

2023

  1. Integrated flow cytometry and sequencing to reconstruct evolutionary patterns from dysplasia to acute myeloid leukemia

    Blood Advances, Vol. 7, Núm. 1, pp. 167-173

  2. Transcriptional and genomic characterization of measurable residual disease in acute myeloid leukaemia

    British Journal of Haematology

2021

  1. A phase 3 trial of azacitidine versus a semi-intensive fludarabine and cytarabine schedule in older patients with untreated acute myeloid leukemia

    Cancer, Vol. 127, Núm. 12, pp. 2003-2014

  2. Impact of measurable residual disease by decentralized flow cytometry: a PETHEMA real-world study in 1076 patients with acute myeloid leukemia

    Leukemia, Vol. 35, Núm. 8, pp. 2358-2370

  3. Measurable residual disease in elderly acute myeloid leukemia: Results from the PETHEMA-FLUGAZA phase 3 clinical trial

    Blood Advances, Vol. 5, Núm. 3, pp. 760-770

  4. The mutational landscape of acute myeloid leukaemia predicts responses and outcomes in elderly patients from the pethema-flugaza phase 3 clinical trial

    Cancers, Vol. 13, Núm. 10

2015

  1. Panobinostat as part of induction and maintenance for elderly patients with newly diagnosed acute myeloid leukemia: Phase Ib/II panobidara study

    Haematologica, Vol. 100, Núm. 10, pp. 1294-1300

2013

  1. Intravenous Busulfan and Melphalan as a Conditioning Regimen for Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma: A Matched Comparison to a Melphalan-Only Approach

    Biology of Blood and Marrow Transplantation, Vol. 19, Núm. 1, pp. 69-74

2010

  1. Epigenetic regulation of the non-canonical Wnt pathway in acute myeloid leukemia

    Cancer Science, Vol. 101, Núm. 2, pp. 425-432

2002

  1. Cefepime plus amikacin versus pipercillin-tazobactam plus amikacin for initial antibiotic therapy in haematology patients with febrile neutropenia: Results of an open, randomized, multicentre trial

    Journal of Antimicrobial Chemotherapy, Vol. 50, Núm. 1, pp. 79-88

  2. Prognostic value of karyotypic analysis in children and adults with high-risk acute lymphoblastic leukemia included in the PETHEMA ALL-93 trial

    Haematologica, Vol. 87, Núm. 2, pp. 154-166

1999

  1. Primary plasma cell leukemia: Clinical, immunophenotypic, DNA ploidy, and cytogenetic characteristics

    Blood, Vol. 93, Núm. 3, pp. 1032-1037

1996

  1. Myelodysplastic syndromes

    Critical Reviews in Oncology/Hematology, Vol. 23, Núm. 1, pp. 57-93

1993

  1. Alternating combination VCMP/VBAP chemotherapy versus melphalan/prednisone in the treatment of multiple myeloma: A randomized multicentric study of 487 patients

    Journal of Clinical Oncology, Vol. 11, Núm. 6, pp. 1165-1171

1992

  1. Increased expression of natural‐killer‐associated and activation antigens in multiple myeloma

    American Journal of Hematology, Vol. 39, Núm. 2, pp. 84-89

1991

  1. Immunophenotypic heterogeneity of multiple myeloma: influence on the biology and clinical course of the disease

    British Journal of Haematology, Vol. 77, Núm. 2, pp. 185-190

1990

  1. Bone marrow biopsy in myelodysplastic syndromes: morphological characteristics and contribution to the study of prognostic factors

    British Journal of Haematology, Vol. 75, Núm. 1, pp. 26-33

1989

  1. Predicción de la supervivencia en los síndromes mielodisplásicos. Análisis de dos sistemas de puntuación con valor pronóstico.

    Sangre, Vol. 34, Núm. 1, pp. 41-46

  2. Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes: A multivariate analysis of prognostic factors in 370 patients

    Blood, Vol. 74, Núm. 1, pp. 395-408

1988

  1. Factores pronósticos en los síndromes mielodisplásicos. Validación de modelos predictivos de supervivencia obtenidos mediante análisis multivariante.

    Sangre, Vol. 33, Núm. 2, pp. 121-126